Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Perseus Proteomics, Inc. ( (JP:4882) ) has provided an announcement.
Perseus Proteomics Inc. reported several non-operating items for the first nine months of its fiscal year ending March 2026, including subsidy income of ¥53.3 million, foreign exchange gains of ¥8.8 million, and interest income of ¥3.4 million. These gains were partially offset by non-operating share issuance costs of ¥1.7 million, highlighting the impact of financing activities on the company’s bottom line.
The company also booked an extraordinary impairment loss of ¥37.0 million on non-current assets under Japan’s accounting standard for fixed asset impairment. All of these items have been incorporated into its third-quarter financial results, giving investors a clearer view of one-off and non-core factors influencing current profitability and asset valuations.
The most recent analyst rating on (JP:4882) stock is a Hold with a Yen228.00 price target. To see the full list of analyst forecasts on Perseus Proteomics, Inc. stock, see the JP:4882 Stock Forecast page.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc., listed on the Tokyo Stock Exchange Growth market under securities code 4882, operates in the biotechnology and life sciences sector. The company focuses on proteomics-driven research and development, leveraging protein science to create therapeutic and diagnostic applications for healthcare and related markets.
Average Trading Volume: 274,052
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.51B
See more data about 4882 stock on TipRanks’ Stock Analysis page.